Red White & Bloom Brands Past Earnings Performance
Past criteria checks 0/6
Red White & Bloom Brands's earnings have been declining at an average annual rate of -49.3%, while the Pharmaceuticals industry saw earnings growing at 43.4% annually. Revenues have been growing at an average rate of 44.9% per year.
Key information
-49.3%
Earnings growth rate
-21.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 44.9% |
| Return on equity | n/a |
| Net Margin | -154.9% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
It's Down 27% But Red White & Bloom Brands Inc. (CSE:RWB) Could Be Riskier Than It Looks
Oct 09
Investors Aren't Entirely Convinced By Red White & Bloom Brands Inc.'s (CSE:RWB) Revenues
Aug 14Take Care Before Diving Into The Deep End On Red White & Bloom Brands Inc. (CSE:RWB)
Apr 19Slammed 30% Red White & Bloom Brands Inc. (CSE:RWB) Screens Well Here But There Might Be A Catch
Dec 21Little Excitement Around Red White & Bloom Brands Inc.'s (CSE:RWB) Revenues As Shares Take 26% Pounding
Apr 17Lacklustre Performance Is Driving Red White & Bloom Brands Inc.'s (CSE:RWB) 26% Price Drop
Apr 17Red White & Bloom Brands' (CSE:RWB) Promising Earnings May Rest On Soft Foundations
Aug 10Is Red White & Bloom Brands (CSE:RWB) Using Debt In A Risky Way?
Sep 03Revenue & Expenses Breakdown
How Red White & Bloom Brands makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 85 | -131 | 40 | 0 |
| 31 Mar 24 | 84 | -129 | 37 | 0 |
| 31 Dec 23 | 88 | -132 | 34 | 0 |
| 30 Sep 23 | 75 | -223 | 21 | 0 |
| 30 Jun 23 | 80 | -226 | 20 | 0 |
| 31 Mar 23 | 86 | -232 | 25 | 0 |
| 31 Dec 22 | 88 | -236 | 26 | 0 |
| 30 Sep 22 | 83 | -11 | 27 | 0 |
| 30 Jun 22 | 69 | -7 | 38 | 0 |
| 31 Mar 22 | 53 | 7 | 34 | 0 |
| 31 Dec 21 | 37 | -39 | 35 | 0 |
| 30 Sep 21 | 46 | -42 | 33 | 0 |
| 30 Jun 21 | 41 | -48 | 27 | 0 |
| 31 Mar 21 | 31 | -70 | 22 | 0 |
| 31 Dec 20 | 19 | -10 | 15 | 0 |
| 30 Sep 20 | 8 | -35 | 18 | 0 |
| 30 Jun 20 | 2 | -26 | 9 | 0 |
| 31 Mar 20 | 0 | -8 | 11 | 0 |
| 31 Dec 19 | 0 | -13 | 8 | 0 |
| 30 Jun 19 | 0 | -8 | 9 | 0 |
| 31 Dec 18 | 0 | -2 | 2 | 0 |
Quality Earnings: RWB is currently unprofitable.
Growing Profit Margin: RWB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RWB is unprofitable, and losses have increased over the past 5 years at a rate of 49.3% per year.
Accelerating Growth: Unable to compare RWB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RWB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-51.1%).
Return on Equity
High ROE: RWB's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.